Navigation Links
Nanomed to Launch Early Access Program for Revel High-Throughput Direct Measurement Platform for Fragment Screening

Fragment-based lead discovery (FBLD) involves biophysical screening of proteins against libraries of low molecular weight compounds. In this early stage, false positives can be problematic due to high levels of solvents and nonspecific hydrophobic binding. At the same time, it is vital that screening techniques are highly sensitive to detect weak interactions. Nanomed, leading producer of graphene biosensors for pharmaceutical and biotherapeutics research, announces the launch of the Early Access Program for Revel, the first high-throughput direct measurement platform for fragments and small molecules using orthogonal Field Effect Biosensing (FEB) technology.

“Until now, FBLD researchers have had to balance throughput, sensitivity and protein consumption using multiple techniques to cross-check results,” says Nanomed CEO, Ross Bundy. “Revel is on par with ligand-observed NMR in sensitivity and throughput, while using much less protein, even less than thermal shift assays. It is an excellent addition to the arsenal of any scientist who wants to drastically reduce the number of false positives and negatives in their primary screen.”

Revel is a 24-channel direct binding system that is fully automated with a 48-hour walkaway run time, designed to be used with the Nimbus HD liquid handler by Hamilton Robotics. Easy-to-use, built-in software acquires and analyzes data in real time, enabling results for 576 interactions in a day, including analysis. The platform measures up to 10 mM concentrations, ensuring accurate detection of low affinity binding interactions. Revel uses orthogonal FEB technology, a breakthrough electrical sensing technique that is unaffected by optical impediments such as solvents and significantly reduces nonspecific binding.

“We are opening the Revel Early Access Program to experienced researchers with active FBLD screening programs for performance studies and valuable product testing feedback,” continues Mr. Bundy. “Working closely with these development partners is the next step in our vision of bringing accurate, quantitative results to drug discovery pipelines without sacrificing cost or time.”

Nanomed will present Revel at Booth 213 at the 2019 SLAS Conference from February 4 through 6 in Washington, D.C.

About Nanomed

Nanomed is a life science company based in San Diego, California. As the world’s leading manufacturer and developer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clearing up inflammation with pro-resolving nanomedicines
2. New nanomedicine resolves inflammation, promotes tissue healing
3. Nanomedicine Market Expected to Grow at a CAGR of 12.57% by 2016 in New Research Report at
4. Nanomedicine Market is Expected to Reach USD 177.60 Billion Globally in 2019: Transparency Market Research
5. The Medicines Patent Pool (MPP) Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines
6. Nanomedical Diagnostics Announces Scientific Advisory Board of Top Scientists and Medical Researchers
7. Nanomedical Diagnostics launches a new graphene biosensor with unprecedented functionality for small molecule and protein analysis
8. NanoViricides Anti-Virus Technology Published in Handbook of Clinical Nanomedicine
9. Nanomedical Diagnostics CEO and CTO to Introduce Electronic Label-Free Assay Based on Field Effect Biosensing Technology at IDTechEx Show
10. Nanomedical Diagnostics to Present Field Effect Biosensing for Fragment-Based Drug Discovery at SLAS 2017
11. Nanomedical Diagnostics Announces Partnership with Rogue Valley Microdevices, Delivering World’s First Successful High-Volume Manufacturing for Graphene Biosensors
Post Your Comments:
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC bio, ... an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for ... dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... technology in an upcoming episode, scheduled to broadcast 4Q/2019. Check your local listings ... and will educate viewers about how its technology facilitates laboratories to improve efficiency ...
(Date:6/11/2019)... ... 2019 , ... A study released today in STEM CELLS ... to incorporate into human CD34+ cells, modifying their gene expression and increasing their ... cells’ ability to lodge into bone marrow. This research performed by Prof. Sanchez-Guijo’s ...
(Date:5/31/2019)... ... 30, 2019 , ... World Compliance Seminars today announced a ... in Boston, MA. This peer recommended interactive workshop is always selected by professionals ... kick off with a compendial treatment of Data Integrity fundamentals. After laying the ...
Breaking Biology Technology:
(Date:8/15/2019)... ... August 15, 2019 , ... Make IVD tests faster, focus ... That was the message at the world's largest gathering of laboratory professionals and ... for Clinical Chemistry (AACC) Annual Scientific Meeting was held in Anaheim, CA, this ...
(Date:8/14/2019)... ... ... Representatives with MyBioGate announced that China Focus@Biotech Week will be held September 10 at ... with Chinese pharma and investors in healthcare innovation,” said Miao Guo, Vice President of ... part of Biotech Week Boston – the annual biotech festival at the No. 1 ...
(Date:8/9/2019)... ... August 09, 2019 , ... With a demand in ... and more patients will visit urgent care centers (UCC) in the coming years, according ... report, The Market for Urgent Care Centers , is a detailed look at ...
Breaking Biology News(10 mins):